These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10713317)

  • 1. Evaluation of a simple dosage scheme for transition from phenprocoumon to warfarin in oral anticoagulation.
    Kristiansen C; Lassen JF; Dahler-Eriksen BS; Dahler-Eriksen K; Larsen TB; Brandslund I
    Thromb Res; 2000 Apr; 98(2):157-63. PubMed ID: 10713317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Initiation of oral anticoagulant treatment: comparison between different dosage regimens of warfarin and phenprocoumon].
    Kemkes-Matthes B; Matzdorff A; Heidt M; Winkler L; Bernardo A; Bernardo A
    Hamostaseologie; 2002 May; 22(2):47-51. PubMed ID: 12193977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of coumarin-induced over-anticoagulation Annotation.
    Makris M; Watson HG
    Br J Haematol; 2001 Aug; 114(2):271-80. PubMed ID: 11529844
    [No Abstract]   [Full Text] [Related]  

  • 6. [Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic].
    Leiria TL; Pellanda L; Miglioranza MH; Sant'anna RT; Becker LS; Magalhães E; Lima GG
    Arq Bras Cardiol; 2010 Jan; 94(1):41-5. PubMed ID: 20414525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The treatment basis for anticoagulants in horses].
    Sinn D; Wintzer HJ
    Tierarztl Prax; 1990 Oct; 18(5):507-11. PubMed ID: 2264055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon.
    Haustein KO
    Semin Thromb Hemost; 1999; 25(1):5-11. PubMed ID: 10327214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism.
    Brehm K; Schack J; Heilmann C; Blanke P; Geissler HJ; Beyersdorf F
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):309-14; discussion 314-5. PubMed ID: 23423913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. German experience with low intensity anticoagulation (GELIA): protocol of a multi-center randomized, prospective study with the St. Jude Medical valve.
    Horstkotte D; Bergemann R; Althaus U; Babin-Ebell J; Chares M; Dahm M; Eigel P; Elert O; Emmrich K; Geiger AW
    J Heart Valve Dis; 1993 Jul; 2(4):411-9. PubMed ID: 8269143
    [No Abstract]   [Full Text] [Related]  

  • 12. Self- versus conventional management of oral anticoagulant therapy: effects on INR variability and coumarin dose in a randomized controlled trial.
    Christensen TD; Maegaard M; Sørensen HT; Hjortdal VE; Hasenkam JM
    Am J Cardiovasc Drugs; 2007; 7(3):191-7. PubMed ID: 17610346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon.
    Fihn SD; Gadisseur AA; Pasterkamp E; van der Meer FJ; Breukink-Engbers WG; Geven-Boere LM; van Meegen E; de Vries-Goldschmeding H; Antheunissen-Anneveld I; van't Hoff AR; Harderman D; Smink M; Rosendaal FR
    Thromb Haemost; 2003 Aug; 90(2):260-6. PubMed ID: 12888873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of bleeding risk using genetic markers in patients taking phenprocoumon.
    Hummers-Pradier E; Hess S; Adham IM; Papke T; Pieske B; Kochen MM
    Eur J Clin Pharmacol; 2003 Jul; 59(3):213-9. PubMed ID: 12728288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant.
    Albrecht D; Ellis D; Canafax DM; Combs D; Druzgala P; Milner PG; Midei MG
    Thromb Haemost; 2017 Apr; 117(4):706-717. PubMed ID: 28180234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Computer aided dosage management of phenprocoumon anticoagulation therapy. Clinical validation].
    Dissmann R; Cromme LJ; Salzwedel A; Taborski U; Kunath J; Gäbler F; Heyne K; Völler H
    Hamostaseologie; 2014; 34(3):226-32. PubMed ID: 24888786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Avoiding emergency situations under anticoagulant therapy with vitamin K antagonists].
    Dempfle CE; Borggrefe M
    Internist (Berl); 2005 Sep; 46(9):1006-10, 1012-3. PubMed ID: 16082525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction.
    Ufer M; Kammerer B; Kirchheiner J; Rane A; Svensson JO
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Oct; 809(2):217-26. PubMed ID: 15315768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced hepatitis: a rare complication of oral anticoagulants.
    Höhler T; Schnütgen M; Helmreich-Becker I; Mayet WJ; Mayer zum Büschenfelde KH
    J Hepatol; 1994 Sep; 21(3):447-9. PubMed ID: 7836716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Perioperative management of anticoagulation].
    Eisele R; Melzer N; Bramlage P
    Chirurg; 2014 Jun; 85(6):513-9. PubMed ID: 24823997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.